# Pizarra — PT-pseudo_138092c2a6be (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_138092c2a6be
Task: 1

Encounter: Urology - outpatient on 22 Feb 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 52-year-old male
  - PSA: 9.0 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.16 ng/mL²
  - PSA velocity: 1.13 ng/mL/yr
  - Prior PSA: 7.9 ng/mL
  - Prostate volume: 58.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86231947 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Hypertension, Obesity (BMI >30), Osteoarthritis
  - Current medication: amlodipine, lisinopril, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 9 ng/mL. PI-RADS 4. PSAD 0.16. Prostate volume 58 mL. csPCa 0.86.

Vitals: weight 92 kg, height 191 cm, BMI 25.2, BP 134/69 mmHg, HR 75 bpm. Smoking: Current smoker (45 pack-yr).

Chief complaint: Clinical reassessment is required due to a confirmed prior biopsy and a continuing upward PSA trend.

History: First noted for an elevated PSA reading in 2022, this patient has since been managed within the outpatient setting. At fifty-two years of age, he works as a retired shopkeeper, lives with his wife in an assisted-living residence, and navigates daily life using a mobility frame. Moderate lower urinary tract symptoms yield an IPSS score of 16, yet he sustains a rigorous cycling regimen of roughly 30 kilometres three times weekly and restricts alcohol intake to five units per week. His medical background includes hypertension, Obesity (BMI >30), and osteoarthritis, managed with amlodipine, lisinopril, and paracetamol taken as needed. He remains a Current smoker (45 pack-yr). A recent routine surveillance colonoscopy returned normal results, and he reports no fresh pelvic pain or haematuria. A prior systematic biopsy identified low-volume disease, and his PSA continues to climb.

Physical examination: DRE: The prostate presents as symmetrically enlarged with a smooth, firm texture, lacking any palpable nodules or asymmetry. Vital signs remain stable, recording a blood pressure of 134/69 mmHg and a heart rate of 75 bpm. General observation shows a well-nourished individual walking with a standard mobility frame, exhibiting no acute distress or peripheral swelling.

Patient info: retired shopkeeper; Married; Lives in assisted-living facility.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 5 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 16/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy.
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.64 +/- 0.14   (95% CI 0.38-0.91)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.14  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.94 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with the current PSA rise and PI-RADS 4 finding, warrants a re-biopsy or deferral, as the protocol expert found the panel insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context of the patient's high-risk features, such as the combination of a high PSA (9.0 ng/mL), a rising PSA velocity (1.13 ng/mL/yr), and a PI-RADS 4 finding, against the prior positive biopsy status.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy (p=0.64) despite the protocol expert stating the panel is insufficient. This suggests the model failed to weigh the conflict: a prior positive biopsy versus a rising PSA trend and a PI-RADS 4 lesion. The high aleatoric uncertainty (H=0.94) indicates the model is highly uncertain about the correct path given the conflicting data points.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline search suggests that the decision hinges on whether the prior grade is documented and whether the lesion has changed against a previous MRI, as the panel alone cannot settle the case.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Maastricht UMC+ | Imaging Department | 15 February 2025 | multiparametric MRI prostate
The report notes a "roughly 18 mm focal hypointense area located at the base-to-mid junction of the left peripheral zone" with "PI-RADS 4 lesion in the left peripheral zone." It does not explicitly compare this to an earlier study.

get_psa_trend
The serial PSA trend shows a rising trajectory: Jun 2022: 1.7 ng/mL, Feb 2023: 2.6 ng/mL, Oct 2023: 3.9 ng/mL, Jun 2024: 5.9 ng/mL, Feb 2025: 9.0 ng/mL.

get_previous_notes
The notes from 01 Sep 2023 mention a sustained PSA increase, tracking at 5.6 ng/mL after a mid-2022 baseline of 4.8 ng/mL, and that the case was forwarded to urology for evaluation. No prior biopsy grade or explicit surveillance protocol status is detailed.

NOT RETRIEVED
The laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the current information is sufficient to address the core questions regarding prior grade and surveillance status.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- Rising PSA trend: 1.7 ng/mL (Jun 2022) to 9.0 ng/mL (Feb 2025).
- PI-RADS 4 finding in the left peripheral zone.
- Previous notes indicate the case was forwarded to urology for comprehensive evaluation.

AGAINST sampling this patient now:
- Prior biopsy result is documented as "Positive" but the specific ISUP grade or Gleason score is not documented in the retrieved notes or reports.

WHERE THIS LEANS
The evidence strongly supports further investigation due to the significant and sustained rise in PSA and the presence of a PI-RADS 4 lesion, despite the lack of a documented prior grade.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence strongly leans towards biopsy due to the significant PSA rise and PI-RADS 4 finding, despite the missing specific prior biopsy grade, which is the only remaining ambiguity.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision leans toward biopsy because the retrieved evidence showed a significant PSA rise from 1.7 ng/mL to 9.0 ng/mL and a PI-RADS 4 lesion, despite the prior biopsy being positive without a documented grade. The statistical prior suggested biopsy, and the retrieved PSA trend and imaging findings provided the necessary justification to proceed with further investigation.

Variables that carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
